Organization (Industry)
Merrimack Pharmaceuticals (United States)
ClinicalTrials.gov lists Merrimack Pharmaceuticals (United States) as lead sponsor of 25 trials. It has 16 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Merrimack Pharmaceuticals (United States): 25 lead-sponsored trials and 1 legal-entity registration.
Disease areas (27)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 10 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Lung Neoplasms | 6 |
| Head and Neck Neoplasms | 5 |
| Colorectal Neoplasms | 4 |
Showing 5 of 27 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 4 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 2 |
| 2011 | 8 |
| 2010 | 4 |
| 2009 | 1 |
| 2008 | 1 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: none of the 25 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (16)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| FLUOROURACIL | 2 |
| Calcium Leucovorin | 2 |
| GEMCITABINE | 3 |
| TRASTUZUMAB | 2 |
| "Capecitabine" | 1 |
Showing 5 of 16 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| not enough data | 1 of 1 on time (n=1) |
Journals published in (14)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| European journal of cancer (Oxford, England : 1990) | 2 |
| American journal of clinical oncology | 1 |
| Annals of oncology : official journal of the European Society for Medical Oncology | 1 |
| BMC cancer | 1 |
| Cancer science | 1 |
Showing 5 of 14 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 52 | 1 | 2025-10-07 |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Brown University | Co sponsors trial with | 1 |
| Elevation Oncology | Co sponsors trial with | 1 |
Latest dated events (81)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-10-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2020-02-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2019-04-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2019-01-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2018-10-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 81 events.
Biomarker capability evidence (83)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| CISH | Trial sponsor | Named in trial inclusion criteria |
| CRP | Trial sponsor | Named in trial inclusion criteria |
| ERBB2 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 83 evidence rows.
On Scientist.com
Merrimack Pharmaceuticals (United States) is listed as a research supplier in the Scientist.com network.
Systems Biology at Merrimack integrates the fields of biology, computing and engineering. We use these tools to gain a more comprehensive understanding of the dynamics of cancer. Rather than focus on individual molecules, our discovery efforts seek to encompass the complexity of entire biological networks. Our foundation is data-driven. We build predictive computational models of tumor biology and using simulation to drive the productivity and precision of our research. Our systems research is comprehensive to all levels of tumor biology, spanning the biochemical interactions...
Show the full description
Systems Biology at Merrimack integrates the fields of biology, computing and engineering. We use these tools to gain a more comprehensive understanding of the dynamics of cancer. Rather than focus on individual molecules, our discovery efforts seek to encompass the complexity of entire biological networks. Our foundation is data-driven. We build predictive computational models of tumor biology and using simulation to drive the productivity and precision of our research. Our systems research is comprehensive to all levels of tumor biology, spanning the biochemical interactions of intracellular signaling networks to systems pharmacology.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Merrimack on Scientist.com
For prices, more details, or to contact Merrimack, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.